Literature DB >> 28116478

Comment on Fu, J. and Chen, Y.: The efficacy and safety of 5 mg/d vortioxetine compared to placebo for major depressive disorder: a meta-analysis.

Eduardo C Humes1,2, Andre R Brunoni3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28116478     DOI： 10.1007/s00213-017-4531-y

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN： 0033-3158            Impact factor:   4.530


× No keyword cloud information.
  8 in total

Review 1.  Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis.

Authors: 
Journal:  Lancet       Date:  2003-03-08       Impact factor: 79.321

2.  A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.

Authors:  Atul R Mahableshwarkar; Paula L Jacobsen; Yinzhong Chen
Journal:  Curr Med Res Opin       Date:  2013-01-17       Impact factor: 2.580

3.  A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder.

Authors:  Neven Henigsberg; Atul R Mahableshwarkar; Paula Jacobsen; Yinzhong Chen; Michael E Thase
Journal:  J Clin Psychiatry       Date:  2012-07       Impact factor: 4.384

Review 4.  A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults.

Authors:  Michael E Thase; Atul R Mahableshwarkar; Marianne Dragheim; Henrik Loft; Eduard Vieta
Journal:  Eur Neuropsychopharmacol       Date:  2016-03-25       Impact factor: 4.600

5.  A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.

Authors:  Rakesh Jain; Atul R Mahableshwarkar; Paula L Jacobsen; Yinzhong Chen; Michael E Thase
Journal:  Int J Neuropsychopharmacol       Date:  2012-09-11       Impact factor: 5.176

6.  The efficacy and safety of 5 mg/d Vortioxetine compared to placebo for major depressive disorder: A meta-analysis.

Authors:  Jie Fu; Yangmei Chen
Journal:  Psychopharmacology (Berl)       Date:  2014-05-29       Impact factor: 4.530

7.  A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder.

Authors:  Cornelius Katona; Thomas Hansen; Christina Kurre Olsen
Journal:  Int Clin Psychopharmacol       Date:  2012-07       Impact factor: 1.659

8.  A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder.

Authors:  Enric Alvarez; Victor Perez; Marianne Dragheim; Henrik Loft; Francesc Artigas
Journal:  Int J Neuropsychopharmacol       Date:  2011-07-18       Impact factor: 5.176
  8 in total
  1 in total

1.  The efficacy of psychotherapies and pharmacotherapies for mental disorders in adults: an umbrella review and meta-analytic evaluation of recent meta-analyses.

Authors:  Falk Leichsenring; Christiane Steinert; Sven Rabung; John P A Ioannidis
Journal:  World Psychiatry       Date:  2022-02       Impact factor: 49.548
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.